Shanghai Shen Lian Biomedical Corp (688098) - Total Liabilities
Based on the latest financial reports, Shanghai Shen Lian Biomedical Corp (688098) has total liabilities worth CN¥133.33 Million CNY (≈ $19.51 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Shanghai Shen Lian Biomedical Corp - Total Liabilities Trend (2013–2025)
This chart illustrates how Shanghai Shen Lian Biomedical Corp's total liabilities have evolved over time, based on quarterly financial data. See 688098 working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Shanghai Shen Lian Biomedical Corp Competitors by Total Liabilities
The table below lists competitors of Shanghai Shen Lian Biomedical Corp ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Beijing Bewinner Communications Co Ltd
SHE:002148
|
China | CN¥148.73 Million |
|
Tae Kwang Corporation
KQ:023160
|
Korea | ₩71.20 Billion |
|
PVA TePla AG
XETRA:TPE
|
Germany | €151.58 Million |
|
Jiangsu Phoenix Property Investment Co Ltd
SHG:600716
|
China | CN¥1.87 Billion |
|
Akis Gayrimenkul Yatirim Ortakligi AS
IS:AKSGY
|
Turkey | TL7.91 Billion |
|
ZH.JIN.ENV.HLDG DL-00001
F:3UG
|
Germany | €16.01 Billion |
|
Hexagon Purus As
OL:HPUR
|
Norway | Nkr3.05 Billion |
|
Nepes Corporation
KQ:033640
|
Korea | ₩458.11 Billion |
Liability Composition Analysis (2013–2025)
This chart breaks down Shanghai Shen Lian Biomedical Corp's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 688098 company net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.00 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.10 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.09 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Shanghai Shen Lian Biomedical Corp's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Shanghai Shen Lian Biomedical Corp (2013–2025)
The table below shows the annual total liabilities of Shanghai Shen Lian Biomedical Corp from 2013 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥143.41 Million ≈ $20.99 Million |
+11.61% |
| 2024-12-31 | CN¥128.50 Million ≈ $18.80 Million |
+47.82% |
| 2023-12-31 | CN¥86.93 Million ≈ $12.72 Million |
-19.67% |
| 2022-12-31 | CN¥108.21 Million ≈ $15.83 Million |
-13.76% |
| 2021-12-31 | CN¥125.48 Million ≈ $18.36 Million |
+6.15% |
| 2020-12-31 | CN¥118.20 Million ≈ $17.30 Million |
-28.93% |
| 2019-12-31 | CN¥166.33 Million ≈ $24.34 Million |
-8.20% |
| 2018-12-31 | CN¥181.18 Million ≈ $26.51 Million |
+26.77% |
| 2017-12-31 | CN¥142.92 Million ≈ $20.91 Million |
+0.42% |
| 2016-12-31 | CN¥142.32 Million ≈ $20.83 Million |
-17.69% |
| 2015-12-31 | CN¥172.90 Million ≈ $25.30 Million |
-39.82% |
| 2014-12-31 | CN¥287.32 Million ≈ $42.04 Million |
+40.88% |
| 2013-12-31 | CN¥203.94 Million ≈ $29.84 Million |
-- |
About Shanghai Shen Lian Biomedical Corp
Shanghai Shen Lian Biomedical Corporation engages in the research, development, production, and sale of veterinary biological products in China. It develops synthetic peptide vaccines to treat foot-and-mouth diseases. The company was founded in 2001 and is headquartered in Shanghai, China.